Skip to main content
4SC AG logo

4SC AG — Investor Relations & Filings

Ticker · VSC ISIN · DE000A3E5C40 LEI · 391200QOKN7LGVP0RQ86 F Manufacturing
Open in API
Filings indexed 719 across all filing types
Latest filing 2019-01-28 Legal Proceedings Report
Country DE Germany
Listing F VSC

About 4SC AG

https://www.4sc.com/

4SC AG is a biopharmaceutical company that formerly focused on the research and development of small-molecule drugs for cancer treatment. The company's strategy centered on addressing diseases with high unmet medical needs by developing innovative therapies that targeted epigenetic mechanisms of action. According to the company's official statements, it currently has no products under development and no operational business.

Recent filings

Filing Released Lang Actions
4SC's pivotal RESMAIN study of resminostat in CTCL receives second positive safety review
Legal Proceedings Report Classification · 1% confidence The document is a press release dated January 28, 2019, originating from 4SC AG, disseminated via DGAP-News. It announces a positive safety review for their pivotal RESMAIN study concerning the drug resminostat in CTCL patients. The content focuses on clinical trial updates, study progress, and future expectations (top-line results in H1 2020). This type of announcement, detailing operational or clinical progress rather than formal financial results (like 10-K or ER), is typically classified as a general corporate news release. Since there is no specific category for clinical trial updates, and it is not a formal financial report, a dividend notice, or a management change, it fits best under the general regulatory announcement/news category, which is RNS (Regulatory Filings) as per the provided definitions, or potentially ER if it were tied to a specific reporting period, but it is clearly a study update. Given the context of a 'News Details' header and DGAP distribution, RNS is the most appropriate fallback for non-standard corporate news.
2019-01-28 English
4SC AG: 4SC's domatinostat (4SC-202) begins Phase II gastrointestinal cancer clinical trial
Regulatory Filings Classification · 1% confidence The document is a press release dated January 14, 2019, announcing that 4SC AG's drug candidate, domatinostat, has begun a Phase II clinical trial (EMERGE study) for gastrointestinal cancer. It details the study design, quotes the investigator and the CEO, and provides background information on the drug and the company. This type of announcement, detailing clinical trial progress and scientific updates, is characteristic of general corporate news releases related to R&D activities. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a specific financial report (IR, AR). Since it is a general corporate announcement about clinical progress, and there is no specific category for clinical trial updates, the most appropriate fallback category is Regulatory Filings (RNS), as it is a general news dissemination service (DGAP) announcement that doesn't fit the other specific financial/governance categories.
2019-01-14 English
4SC AG: Positive safety review of 4SC's Phase Ib/II SENSITIZE study of domatinostat (4SC-202) + pembrolizumab in melanoma
Regulatory Filings Classification · 1% confidence The document is a press release dated December 27, 2018, announcing a positive safety review for a clinical study (SENSITIZE) involving the drug domatinostat. It details the progression to the next dose cohort and provides updates on clinical development plans. This type of announcement, focusing on clinical trial progress and safety data evaluation, is typically classified as an Earnings Release (ER) if it were tied to a quarterly report, or more generally as a Regulatory Filing (RNS) if it's a specific, non-financial operational update. Since it is a news announcement about clinical trial progress and safety review outcomes, and not a full financial report (10-K, IR), a management discussion (MDA), or a formal earnings release (ER) detailing P&L, the most appropriate general category for a specific operational update disseminated via a news service (DGAP) that doesn't fit other specific categories is Regulatory Filings (RNS). However, given the content is a direct update on drug development progress, it often falls under the broader umbrella of investor news. Comparing the options, it is not a formal financial report, a management discussion, or a call transcript. It is a specific operational update. Since there is no specific 'Clinical Trial Update' code, RNS serves as the best fit for a general regulatory/news announcement not covered elsewhere.
2018-12-27 English
4SC reaches significant milestone with enrollment of 100 patients in pivotal RESMAIN study of resminostat as CTCL maintenance therapy
Regulatory Filings Classification · 1% confidence The document is a press release dated November 20, 2018, announcing a clinical trial milestone (enrollment of 100 patients in the pivotal RESMAIN study) for a drug candidate (resminostat). It discusses study progress, expected top-line results (H1 2020), and future regulatory submission plans. This content is typical of an update on clinical development and operational progress, often released via regulatory news services (like DGAP, mentioned at the end). Since it is not a full financial report (10-K, IR), an earnings release (ER), or a formal presentation (IP), and it is a specific operational update, it fits best under the general 'Regulatory Filings' (RNS) category, which serves as a broad category for corporate news announcements that don't fit more specific financial or governance codes. It is not a Report Publication Announcement (RPA) because it is reporting on study progress, not announcing the publication of a separate, attached report.
2018-11-20 English
4SC receives milestone payment from Link Health
Regulatory Filings Classification · 1% confidence The document is a press release dated October 31, 2018, announcing that 4SC AG received a milestone payment from its partner Link Health regarding the cancer therapeutic candidate 4SC-205. It details the terms of the licensing agreement and provides commentary from the CEO. This type of announcement, which reports on a specific corporate event (receiving a payment related to a partnership/development milestone) and is disseminated via a news service (DGAP), typically falls under general corporate news or regulatory announcements. Since it is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a specific capital action (CAP, SHA), the most appropriate general category for a non-standard corporate update disseminated as news is 'Regulatory Filings' (RNS), which serves as the fallback for miscellaneous regulatory announcements not covered by other specific codes. The document length is substantial enough (7113 chars) that it is not merely an announcement of a report (RPA).
2018-10-31 English
Report Publication Announcement 2018
Report Publication Announcement Classification · 1% confidence The document is extremely short (1552 characters) and explicitly states that it is a 'Preliminary announcement of the publication of financial reports'. It specifies the report type ('Annual financial report') and provides the future 'Date of disclosure' (March 20, 2019), along with links. According to Rule #2 (The 'MENU VS MEAL' Rule), a document announcing the future publication of a report, rather than containing the report itself, should be classified as a Report Publication Announcement (RPA).
2018-10-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.